# Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

> **NCT04406857** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Locally Advanced Rectal Carcinoma
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v8
- Stage III Rectal Cancer AJCC v8

## Interventions

- **DRUG:** Capecitabine
- **RADIATION:** Radiation Therapy
- **DRUG:** Ropidoxuridine

## Key facts

- **NCT ID:** NCT04406857
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-01-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406857, "Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04406857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*